BiotechTube

Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧬Featured in Oncology Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

First-line Treatment of Metastatic Pancreatic Cancer

Conditions

First-line Treatment of Metastatic Pancreatic Cancer

Trial Timeline

Dec 2, 2025 → Dec 1, 2028

NCT ID
NCT07238283

About Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine

Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for First-line Treatment of Metastatic Pancreatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07238283. Target conditions include First-line Treatment of Metastatic Pancreatic Cancer.

What happened to similar drugs?

0 of 2 similar drugs in First-line Treatment of Metastatic Pancreatic Cancer were approved

Approved (0) Terminated (0) Active (2)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄HRS-4642 + AG + HRS-4642 placebo + AGJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07238283Phase 3Recruiting

Competing Products

2 competing products in First-line Treatment of Metastatic Pancreatic Cancer

See all competitors
ProductCompanyStageHype Score
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
47
HRS-4642 + AG + HRS-4642 placebo + AGJiangsu Hengrui MedicinePhase 3
47